Screener
Travere Therapeutics, Inc. TVTX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Assets | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Accrued expenses | 104,408 | 126,035 |
| Operating lease liabilities, current portion | 6,017 | 5,875 |
| Other current liabilities | 2,100 | 3,194 |
| Total current liabilities | 125,437 | 159,904 |
| Convertible debt | 312,079 | 311,724 |
| Operating lease liabilities, less current portion | 9,566 | 11,134 |
| Other non-current liabilities | 9,378 | 7,601 |
| Total liabilities | 456,460 | 490,363 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s total current liabilities?
- Travere Therapeutics, Inc. (TVTX) reported total current liabilities of $125.44M in Q1 2026.
- How has Travere Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Travere Therapeutics, Inc.'s total current liabilities decreased by 31.3% year-over-year, from $182.46M to $125.44M.
- What is the long-term trend for Travere Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s total current liabilities has grown at a 11.5% compound annual growth rate (CAGR), from $92.66M to $159.9M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Travere Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude